抗血栓薬/抗凝固薬: 技術と世界市場

Report Overview

The global market for antithrombotic/anticoagulant drugs is estimated to grow from $31.6 billion in 2023 to reach $46.2 billion by 2028, at a compound annual growth rate (CAGR) of 7.9% from 2023 through 2028.

Summary:

Analysis revealed that the fastest-growing market segment is thrombin inhibitors, with a predicted CAGR of REDACTED%. The anticoagulants segment has the slowest growth rate, with a CAGR of REDACTED%.

The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs –

• Recent innovations and the emergence of novel thrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-REDACTED%) and Innohep (-REDACTED%), have seen a significant decrease in the market.
• The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitors grows.
• The market for thrombin inhibitors is expected to grow at the highest CAGR of REDACTED% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitors.
• An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products.

Report Scope:

This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market.

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028.

Report Synopsis

Report Includes:

• 59 data tables and 35 additional tables
• Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years
• Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region
• In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19
• A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity
• Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments
• Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers
• Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
• Profiles of the leading market players

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
What’s New in This Report?
Scope of Report
Research Methodology
Information Sources
Geographic Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market Overview
Overview of Cardiovascular Disease
Coronary Artery Disease
Atherosclerosis
Angina (Angina Pectoris)
Acute Myocardial Infarction
Medical Management
Lifestyle Changes
Diet Modification
Smoking Cessation
Pharmaceuticals
Anticoagulants and Antiplatelet Drugs
Major Drivers
Coagulation Factors Targeted to Reduce CVD
The Global Burden of Cardiovascular Disease
2030 Global Burden of Cardiovascular Disease
The Global Economic Burden of Cardiovascular Disease
Sales Performance of Major Drugs in 2022
Chapter 4 Global Market for Anticoagulant Drugs
Overview
Products
Low Molecular Weight Heparin
Oral Anticoagulants (Vitamin K Antagonists)
Global Anticoagulant Drugs Market Forecast
Chapter 5 Global Market for Antiplatelet Drugs
Overview
Products
Oral Antiplatelets
Global Antiplatelet Drugs Market Forecast
Chapter 6 Global Market for Thrombin Inhibitors
Overview
Products
Direct Thrombin Inhibitors
Thrombolytic Agents
Direct Factor Xa Inhibitors
Global Thrombin Inhibitors Market Forecast
Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World
Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
Introduction to ESG
Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
Key ESG Issues
Consumer Attitudes Towards ESG
Industry ESG Performance Analysis
Case Study
Concluding Remarks from BCC
Chapter 9 Clinical Trials and Patent Landscape
Clinical Trials Analysis
Patent Analysis
Patent by Assignee
Chapter 10 M&A and Venture Funding Outlook
M&A Analysis
Chapter 11 Competitive Landscape
Chapter 12 Company Profiles
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
MERCK & CO. INC.
PFIZER INC.
SANOFI
Chapter 13 Appendix
Government Regulatory Agencies and Professional Organizations

List of Tables
Summary Table : Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, Through 2028
Table 1 : Standard Angina Pectoris Classification
Table 2 : Top 20 Leading Causes of Death, 2019
Table 3 : Estimated Deaths Due to Noncommunicable Diseases, by Sex and Disease, 2019
Table 4 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2019
Table 5 : Global Health Estimates, by Sex and WHO Region, 2019
Table 6 : Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2030
Table 7 : Estimated Deaths Due to Cardiovascular Disease, by Sex and WHO Region, 2030
Table 8 : Economic Burden of NCDs in India, 2012-2030
Table 9 : Praxbind (Idarucizumab) Drug Label
Table 10 : Global Market for Thrombin Inhibitors Drugs, by Type, 2022
Table 11 : Global Market for Anticoagulant Drugs, by Type, 2022
Table 12 : Global Market for Antiplatelet Drugs, by Type, 2022
Table 13 : Lovenox Drug Label
Table 14 : Fragmin Drug Label
Table 15 : Innohep Drug Label
Table 16 : Global Market for Anticoagulant Drugs, by Region, Through 2028
Table 17 : Global Market for Anticoagulant Drugs, by Type, Through 2028
Table 18 : Global Market for Low Molecular Weight Heparin Anticoagulant Drugs, by Region, Through 2028
Table 19 : Global Market for Oral Anticoagulant Drugs, by Region, Through 2028
Table 20 : Plavix Drug Label
Table 21 : Pletal Drug Label
Table 22 : Effient Drug Label
Table 23 : Global Market for Antiplatelets, by Type, Through 2028
Table 24 : Global Market for Antiplatelets, by Region, Through 2028
Table 25 : Global Market for Oral Antiplatelets, by Region, Through 2028
Table 26 : Global IV Market for Antiplatelets, by Region, Through 2028
Table 27 : Global Market for Thrombin Inhibitors, by Type, Through 2028
Table 28 : Global Market for Thrombin Inhibitors, by Region, Through 2028
Table 29 : Global Market for Direct Factor Xa Inhibitors, by Region, Through 2028
Table 30 : Global Market for Direct Thrombin Inhibitors, by Region, Through 2028
Table 31 : Global Market for Direct Thrombolytic Agents, by Region, Through 2028
Table 32 : Global Market for Antithrombotic/Anticoagulant Drugs, by Region, Through 2028
Table 33 : North American Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 34 : North American Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 35 : North American Market for Anticoagulant Drugs, by Type, Through 2028
Table 36 : North American Market for Antiplatelets, by Type, Through 2028
Table 37 : North American Market for Thrombin Inhibitors, by Type, Through 2028
Table 38 : European Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 39 : European Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 40 : European Market for Anticoagulant Drugs, by Type, Through 2028
Table 41 : European Market for Antiplatelets, by Type, Through 2028
Table 42 : European Market for Thrombin Inhibitors, by Type, Through 2028
Table 43 : Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 44 : Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 45 : Asia-Pacific Market for Anticoagulant Drugs, by Type, Through 2028
Table 46 : Asia-Pacific Market for Antiplatelets, by Type, Through 2028
Table 47 : Asia-Pacific Market for Thrombin Inhibitors, by Type, Through 2028
Table 48 : Rest of the World Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 49 : Rest of the World Market for Anticoagulant Drugs, by Type, Through 2028
Table 50 : Rest of the World Market for Antiplatelets, by Type, Through 2028
Table 51 : Rest of the World Thrombin Inhibitors Drugs Market, by Type, Through 2028
Table 52 : Key Focus Areas in ESG Metrics: Market for Antithrombotic/Anticoagulant Drugs
Table 53 : Typical ESG Factors in Pharmaceuticals
Table 54 : Net-Zero GHG Commitments by Major Antithrombotic/Anticoagulant Drug Manufacturing Companies
Table 55 : ESG Rankings for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2023*
Table 56 : CDP Scope Card for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2022
Table 57 : Selected Thrombin Drugs in Clinical Trials, as of 2023
Table 58 : Selected Granted Thrombosis Treatment Drugs in Clinical Trials, as of 2023
Table 59 : Patents Issued on Anticoagulant Drugs, by Assignee Company, 2018-2022
Table 60 : Patents Issued on Thrombin Inhibitor Drugs, by Assignee Company, 2018-2022
Table 61 : Patents Issued on Antiplatelet Drugs, by Assignee Company, 2018-2022
Table 62 : Global Market for Antithrombotic/Anticoagulant Drugs’ Recent Mergers and Acquisitions
Table 63 : Global Market for Antithrombotic/Anticoagulant Drugs Revenue Analysis, 2022
Table 64 : Global Market for Antithrombotic/Anticoagulant Drugs Key Product Portfolio, 2022
Table 65 : Global Thrombin Inhibitors Drugs Market Revenue Analysis, 2022
Table 66 : Global Anticoagulants Drug Market Revenue Analysis, 2022
Table 67 : Global Antiplatelet Drugs Market Revenue Analysis, 2022
Table 68 : Bayer AG: Marketed Products
Table 69 : Bayer AG: Key Financials, 2021 and 2022
Table 70 : Bayer AG: Key Developments, 2022 and 2023
Table 71 : Boehringer Ingelheim: Selected Key Developments, 2019-2021
Table 72 : Bristol-Myers Squibb: Key Developments, 2020 and 2021
Table 73 : Daiichi Sankyo: Product Information
Table 74 : Daiichi Sankyo: Annual Revenue, 2020-2022
Table 75 : Daiichi Sankyo: Key Developments, 2018-2023
Table 76 : Roche: Financials, 2021 and 2022
Table 77 : Roche: Revenues, by Business Segment, 2016-2021
Table 78 : Roche: Product Portfolio
Table 79 : Roche: Diagnostics Patient Monitoring Product Portfolio
Table 80 : Roche: Recent Developments, 2019-2022
Table 81 : Johnson & Johnson: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
Table 82 : Johnson & Johnson: Financials, 2021
Table 83 : Johnson & Johnson: Product Portfolio
Table 84 : Johnson & Johnson: Recent Developments and Strategies, 2017-2022
Table 85 : Merck & Co. Inc.: Products Portfolio for Antithrombotic/Anticoagulant Drug Treatment
Table 86 : Merck & Co. Inc.: Financial Performance, 2018-2022
Table 87 : Pfizer Inc.: Product Segments
Table 88 : Pfizer Inc.: Key Financials, 2021
Table 89 : Sanofi: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
Table 90 : Sanofi: Business Segments
Table 91 : Sanofi: Financial Performance,2021 and 2022
Table 92 : Sanofi: Key Developments, 2019-2023
Table 93 : Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers

List of Figures
Summary Figure : Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, 2020-2028
Figure 1 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2019
Figure 2 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2019
Figure 3 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2019
Figure 4 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2019
Figure 5 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2030
Figure 6 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2030
Figure 7 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2030
Figure 8 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2030
Figure 9 : Projected Total Costs of Cardiovascular Disease in the United States, 2015-2030
Figure 10 : Global Market for Antithrombotic/Anticoagulant Drugs, by Region
Figure 11 : Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Region, 2022
Figure 12 : How a Strong ESG Proposition Benefits Businesses
Figure 13 : Global ESG-Adoption Level Across All the Industries, 2021 and 2022
Figure 14 : The Ten Business Sustainability Trends Identified for 2022
Figure 15 : Pfizer Inc.’s Most Material ESG Issues, 2020
Figure 16 : Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Company, 2022
Figure 17 : Global Market Shares of Thrombin Inhibitors Drugs, by Company, 2022
Figure 18 : Global Market Shares of Anticoagulant Drugs, by Company, 2022
Figure 19 : Global Market Shares of Antiplatelet Drugs, by Company, 2022
Figure 20 : Boehringer Ingelheim: Annual Revenue, 2021 and 2022
Figure 21 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021 and 2022
Figure 22 : Boehringer Ingelheim: Revenue Share, by Region, 2021 and 2022
Figure 23 : Bristol-Myers Squibb: Revenue Share, by Region/Country, 2022
Figure 24 : Daiichi Sankyo: Market Share, by Region/Country, 2022
Figure 25 : Roche: Annual Revenue, 2021 and 2022
Figure 26 : Roche: Market Share, by Business Segment, 2022
Figure 27 : Roche: Revenue Share, by Business Segment, 2021
Figure 28 : Roche: Revenue Share, by Region/Country, 2021
Figure 29 : Johnson & Johnson: Financials, 2017-2021
Figure 30 : Johnson & Johnson: Revenue Share, by Region/Country, 2021
Figure 31 : Johnson & Johnson: Revenue Share, by Business Segment, 2021
Figure 32 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2022
Figure 33 : Merck & Co. Inc.: Revenue Share, by Region, 2022
Figure 34 : Pfizer Inc.: Revenue Share, by Region, 2021
Figure 35 : Pfizer Inc.: Revenue Share, by Business Segment, 2021
Figure 36 : Sanofi: Net Sales Share, by Business Segment, 2022
Figure 37 : Sanofi: Net Sales Share, by Region/Country, 2022